




# SCIENTIFIC PROGRAMS

Fall 2024/Spring 2025 | [AACR.org/Calendar](https://AACR.org/Calendar)

**AACR** American Association  
for Cancer Research®


# 2024-2025 SCIENTIFIC PROGRAMS



## The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

September 21-24, 2024 | Los Angeles, CA

PAGE  
4



## Tumor Immunology and Immunotherapy

October 18-21, 2024 | Boston, MA

PAGE  
5



## EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 23-25, 2024 | Barcelona, Spain

PAGE  
6

### SAVE THE DATE

#### Frontiers in Cancer Science 2024


November 13-15, 2024 | Biopolis, Singapore



## Liquid Biopsy: From Discovery to Clinical Implementation

November 13-16, 2024 | San Diego, CA


PAGE  
7



## RNAs as Drivers, Targets, and Therapeutics in Cancer

November 14-17, 2024 | Bellevue, WA

PAGE  
8



## Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer

November 17-20, 2024 | Boston, MA

PAGE  
9

### SAVE THE DATE

#### AACR-KCA Joint Conference on Precision Medicine in Cancer

November 21-22, 2024 | Seoul, Korea



## Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry

December 9-11, 2024 | Toronto, ON, Canada

PAGE  
10



## San Antonio Breast Cancer Symposium

December 10-13, 2024 | San Antonio, TX

PAGE  
11



## Translating Targeted Therapies in Combination with Radiotherapy

January 26-29, 2025 | San Diego, CA

PAGE  
12



## DNA Methylation, Clonal Hematopoiesis, and Cancer

February 1-4, 2025 | San Diego, CA

PAGE  
13

### SAVE THE DATE

#### 13th AACR-JCA Joint Conference: From Cancer Discovery Science to Therapeutic Innovation

February 1-5, 2025 | Maui, HI



## AACR IO

February 23-26, 2025 | Los Angeles, CA

PAGE  
14



## Acute Lymphoblastic Leukemia

March 7-9, 2025 | San Diego, CA

PAGE  
16



## Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals

March 11-13, 2025 | Boston, MA

PAGE  
17

### SAVE THE DATE

#### AACR Oncology Industry Partnering Event

April 24-25, 2025 | Chicago, IL



## International Conference on Malignant Lymphoma (ICML)

June 17-21, 2025 | Lugano, Switzerland

PAGE  
18





# AACR

American Association  
for Cancer Research®

# ANNUAL MEETING 2025 CHICAGO



UNIFYING  
**CANCER  
SCIENCE AND  
MEDICINE:**  
A CONTINUUM OF  
**INNOVATION  
FOR IMPACT**

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs.

**APRIL 25-30, 2025**

[AACR.ORG/AACR25](https://AACR.ORG/AACR25) | #AACR25



Continuing Medical Education Activity  
-AMA PRA Category 1 Credits™ available

## CALL FOR ABSTRACTS

**ABSTRACT SUBMISSION DEADLINE:**  
NOVEMBER 26, 2024

**LATE-BREAKING AND CLINICAL TRIALS ABSTRACT SUBMISSION DEADLINE:**  
JANUARY 2025

# GENERAL INFORMATION

## AMERICAN ASSOCIATION FOR CANCER RESEARCH® (AACR)

The authoritative source of information about advances in the etiology, diagnosis, treatment, and prevention of cancer. The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer throughout the world.

## ABOUT AACR SCIENTIFIC PROGRAMS

The AACR organizes a variety of outstanding conferences, meetings, and workshops each year to advance our understanding of cancer and to facilitate the exchange of the most cutting-edge research in the field. AACR meetings highlight the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their areas of expertise, and learn how to apply exciting new concepts, tools, and techniques to their own research.

AACR Special Conferences present unique opportunities to interact with the world's leading experts and discuss the latest findings in rapidly developing areas of cancer research. These popular conferences are relatively small (150-400 attendees) to allow ample time

for discussion and networking. The AACR's educational workshops provide early-career investigators with opportunities to develop skills in clinical trial design, molecular biology, integrative molecular epidemiology, translational research, and related fields. Many programs supplement the educational aspects with mentoring, networking, and career development opportunities. Coupled with a broad array of educational and career development sessions at the Annual Meeting and year-round initiatives, these programs prepare younger researchers for the next vital steps in their careers.

The AACR also partners with international organizations to present high-level, quality scientific conferences focused on cancer research around the world.



## CONTINUING MEDICAL EDUCATION

AMA PRA Category 1 Credits™ are available for participation in many of our meetings. Visit [AACR.org/CME](https://www.aacr.org/CME) to learn more and see a full list of CME activities.

## FINANCIAL SUPPORT FOR ATTENDANCE

A variety of award programs are available to offset a portion of the registration, travel, and other expenses incurred in attending an AACR conference. For more information on awards, visit [AACR.org/Calendar](https://www.aacr.org/Calendar) and click on the link for the conferences of interest.

## ABOUT THE COVER IMAGE

Dysregulation of cholesterol homeostasis is closely associated with advanced hepatocellular carcinoma (HCC). SPARC plays an important role in facilitating the cholesterol-dependent invasion phenotype in HCC. The cover image depicts a liver-shaped vessel filled with sparks, symbolizing the increased expression of SPARC in the diseased liver. *Cancer Research*, June 1, 2024, Volume 84, Issue 11.



## MEMBERSHIP

AACR membership is open to scientists, clinicians, advocates, and others interested in joining a worldwide network of professionals devoted to cancer research. Members enjoy an array of benefits, including discounted registration rates for conferences, reduced subscription rates to the AACR's ten scientific journals, abstract sponsorship privileges for AACR Annual Meetings, and ample networking opportunities. To join the AACR and take advantage of discounted conference rates, visit [AACR.org/Membership](https://www.aacr.org/Membership).

## SUPPORT OPPORTUNITIES

Support from philanthropic foundations and corporate underwriters for these conferences and workshops is welcomed and encouraged. To discuss AACR opportunities and how you may participate, please contact the corporate alliances team at [corporaterequests@aacr.org](mailto:corporaterequests@aacr.org).

For updates on any conference or workshop not featured in this book, please visit [AACR.org](https://www.aacr.org).





17th AACR Conference on

# THE SCIENCE OF CANCER HEALTH DISPARITIES IN RACIAL/ETHNIC MINORITIES AND THE MEDICALLY UNDERSERVED

IN ASSOCIATION WITH THE AACR MINORITIES IN CANCER RESEARCH COUNCIL

September 21–24, 2024 | The Westin Bonaventure Hotel & Suites | Los Angeles, CA

**Register Today!**

## COCHAIRS



### **Moon S. Chen**

University of California Davis,  
Davis, CA



### **Melissa B. Davis**

Morehouse School of Medicine,  
Atlanta, GA



### **Carmen E. Guerra**

University of Pennsylvania,  
Philadelphia, PA



### **Adana A.M. Llanos**

Columbia University,  
New York, NY



### **Ruben A. Mesa**

Wake Forest Baptist Comprehensive  
Cancer Center, Winston-Salem, NC



### **Jasmine Plummer**

St. Jude Children's Research  
Hospital, Memphis, TN



### **Susan M. Shinagawa**

Asian & Pacific Islander National  
Cancer Survivors Network,  
Spring Valley, CA

## ABOUT THIS CONFERENCE

This conference is dedicated to advancing the understanding of cancer disparities that pose significant public health challenges. Join experts from academia, industry, government, and the community as we facilitate the exchange of innovative ideas, delve into the latest findings, and catalyze the development of new research initiatives in the field of cancer health disparities.

## SESSION TOPIC HIGHLIGHTS

- Advances in Early Detection and Screening
- Advancing the Science of Cancer in Latinos: Creating a Network of Researchers, Clinicians, and Community Advocates
- Advocacy at the Bench
- Best Practices for Using AI and Big Data to Address Cancer Disparities
- Community Engagement: Patient-driven Solutions to Overcoming Barriers in Health Equity
- Multilevel Interventions to Achieve Representation in Clinical Trials and Cancer Research
- New Cancer Cohorts
- Structural Racism and Cancer Disparities
- Translating Cancer Research to Service and Outreach in American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Populations
- The Science of Cancer Survivorship



Continuing Medical Education (CME) Activity—*AMA PRA Category 1 Credits™* available

#AACRdisp24  
AACR.org/CHD24

**AACR** American Association  
for Cancer Research®



AACR Special Conference in Cancer Research

# TUMOR IMMUNOLOGY AND IMMUNOTHERAPY

IN ASSOCIATION WITH THE CANCER IMMUNOLOGY WORKING GROUP (CIMM)

October 18–21, 2024 | The Westin Copley Place | Boston, MA

**Advance Registration Deadline: September 9**

## COCHAIRS



**Yvonne Y. Chen**

University of California,  
Los Angeles, CA



**Sergio Quezada**

University College London (UCL)  
Cancer Institute, London, England



**Robert D. Schreiber**

Washington University School of  
Medicine of St. Louis, St. Louis, MO



**Fernando Vidal-Vanaclocha**

The George Washington  
University, Washington, D.C.

## ABOUT THIS CONFERENCE

This AACR Special Conference on Tumor Immunology and Immunotherapy is designed to integrate multidisciplinary facets of basic cancer immunology and immunotherapy to broaden our understanding of ways to harness the immune system to treat cancer. The hallmark of this series is also to encourage the effective exchange of ideas between basic cancer immunologists, non-immunologists, and clinical oncologists in order to develop approaches that translate to outcomes. This year's program will once again include a roster of international thought-leaders who will present and discuss new agent development, basic cancer immunobiology, engineering, target discovery, and translation of basic research to early clinical trial development. Speakers and participants will be encouraged to actively engage in panel discussions at the end of each session.

## SESSION TOPIC HIGHLIGHTS


- Cancer Immunology (CIMM) Working Group Session: Novel Approaches in Antigen Target Discovery
- Clinical and Biological Intersection
- Emerging Technologies, Microbiome, and Immunometabolism
- Good and Bad CD4 T-cell Help
- Immune Checkpoint Expression Profiles and Therapeutic Combinations
- Mass Spectrometry / MHC
- Myeloid and NK Cells
- T-cell Engineering / Cellular Therapy



Continuing Medical Education (CME) Activity—*AMA PRA Category 1 Credits™* available

#AACRt14  
AACR.org/T14

**AACR** American Association  
for Cancer Research®



EORTC-NCI-AACR Symposium on

# MOLECULAR TARGETS AND CANCER THERAPEUTICS

October 23-25, 2024

Barcelona International Convention Centre (CCIB) | Barcelona, Spain

**Registration Deadline: September 4**

**Late-Breaking Abstracts: Opens September 18 | Closes September 25**

## COCHAIRS



**E.G. Elisabeth de Vries**

University Medical Centre  
Groningen, Groningen,  
Netherlands (EORTC)



**Tim F. Greten**

National Cancer Institute,  
Bethesda, MD (NCI)



**Timothy A. Yap**

The University of Texas MD  
Anderson Cancer Center,  
Houston, TX (AACR)

## SESSION TOPIC HIGHLIGHTS

- Cell Cycle Inhibitors: Targeting the Cell Cycle in ER+ Breast Cancer and Beyond
- Clinical Trial Methodology Workshop: Surrogacy in Early Drug Development
- Equipoise: Designing Neoadjuvant Trials
- Evolving Regulatory Frameworks for Early Drug Development
- Fine-Tuning the Use of Antibody-Drug Conjugates to Treat Cancer
- Inhibiting KRAS in the Clinic Beyond G12C
- Innovation and Biomarkers in Cancer Drug Development (IBCD) Workshop
- Liquid Biopsy, Tumour Heterogeneity, and Disease Evolution: Monitoring the Path of Drug Development"
- Molecular Matching Patients with Targeted Agents - Co-Mutations and Bioinformatics
- Novel Frontiers for the Immunotherapy of Cancer
- New Drugs on the Horizon
- Optimising of Preclinical Models for Drug Development
- Toward a Fully Automated AI Driven Pipeline?


## ABOUT THIS CONFERENCE

As the premier drug development and translational research meeting, this symposium gives the spotlight to preclinical and phase I studies, ensuring in-depth scientific discussions on the latest developments in targets and drugs. Attracting an international audience of academics, scientists and pharmaceutical industry leaders, this event enables discussions on the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.



#ENASymp24 | AACR.org/Targets





AACR Special Conference in Cancer Research

# LIQUID BIOPSY: FROM DISCOVERY TO CLINICAL IMPLEMENTATION

November 13–16, 2024 | Omni San Diego Hotel | San Diego, CA

**Abstract Deadline: August 27**

**Advance Registration Deadline: October 2**

## COCHAIRS



**Catherine Alix-Panabières**

University of Montpellier,  
Montpellier, France



**Luis A. Diaz, Jr.**

Memorial Sloan Kettering Cancer  
Center, New York, NY



**Maximilian Diehn**

Stanford University,  
Stanford, CA



**Y.M. Dennis Lo**

Chinese University of Hong Kong,  
Hong Kong



**Klaus Pantel**

University Medical Center  
Hamburg-Eppendorf,  
Hamburg, Germany

## ABOUT THIS CONFERENCE

This conference brings together leaders in the field to share the latest advancements in liquid biopsies encompassing the spectrum from discovery to clinical application. Engage in sessions covering the biology of circulating tumor cells, plasma biomarkers, new technologies, early detection, MRD monitoring, tumor evolution, immunotherapy integration, and computational science. Don't miss this unparalleled opportunity to advance cancer research and clinical practice.

## SESSION TOPIC HIGHLIGHTS


- Biology Behind Circulating Tumor Cells (CTCs)
- Biology of Plasma Biomarkers
- New Technologies for Liquid Biopsy Analyses
- Early Detection of Primary Cancer and Relapse
- Liquid Biopsy Detection and Monitoring of MRD
- Monitoring Tumor Evolution in Cancer Patients
- Liquid Biopsy and Immunotherapy
- Computational Science in Liquid Biopsy Analyses



Continuing Medical Education (CME) Activity—*AMA PRA Category 1 Credits™* available

#AACRliqbio24  
AACR.org/LiqBio24

**AACR** American Association  
for Cancer Research®



AACR Special Conference in Cancer Research

# RNAS AS DRIVERS, TARGETS, AND THERAPEUTICS IN CANCER

November 14–17, 2024

Hyatt Regency Bellevue on Seattle's Eastside | Bellevue, WA

**Abstract Deadline: August 26**

**Advance Registration Deadline: October 3**

## COCHAIRS



**Howard Y. Chang**

Stanford University,  
Stanford, CA



**Joshua T. Mendell**

University of Texas Southwestern  
Medical Center, Dallas, TX



**Anastasia Khvorova**

University of Massachusetts Chan  
Medical School, Worcester, MA



**V. Narry Kim**

Seoul National University,  
Seoul, Korea

## ABOUT THIS CONFERENCE

This conference promises to be an illuminating gathering focused on RNAs as pivotal drivers, targets, and therapeutics in cancer. Plenary sessions will delve into cutting-edge research on identifying RNA drivers of cancer progression, targeting them for intervention, and leveraging RNA-based therapeutics and RNA vaccines, alongside discussions on computational methods for uncovering RNA-cancer connections. Engage in conversations about translating RNA-focused discoveries into clinical applications and personalized cancer treatments. Join leading researchers, clinicians, and industry experts for an insightful exchange of ideas and advancements at this transformative event shaping the future of cancer therapy.

## SESSION TOPIC HIGHLIGHTS


- Deregulation of RNA in Cancer
- Design of mRNA Drugs
- Emerging RNA Technologies
- Interaction Between RNA Drugs and the Immune System
- RNA Delivery
- RNAs as Drivers and Targets in Cancer
- Small RNA Therapeutics
- RNA for Cancer Immunotherapy



Continuing Medical Education (CME) Activity—AMA PRA Category 1 Credits™ available

#AACRna24  
AACR.org/RNAs24

**AACR** American Association  
for Cancer Research®



AACR Special Conference in Cancer Research

# TUMOR-BODY INTERACTIONS: THE ROLES OF MICRO- AND MACROENVIRONMENT IN CANCER

IN ASSOCIATION WITH THE AACR TUMOR MICROENVIRONMENT WORKING GROUP (TME)

November 17–20, 2024 | The Westin Copley Place | Boston, MA

**Abstract Deadline: September 3**

**Advance Registration Deadline: October 11**

## COCHAIRS



**Mikala Egeblad**

Cold Spring Harbor Laboratory,  
Cold Spring Harbor, NY



**Neta Erez**

Tel Aviv University,  
Tel Aviv, Israel



**Sergei I. Grivennikov**

Cedars-Sinai Medical Center,  
Los Angeles, CA



**Ilaria Malanchi**

The Francis Crick Institute,  
London, England

## ABOUT THIS CONFERENCE

Recent advancements herald promising strategies to disrupt the intricate co-evolution of tumors and their microenvironment, potentially culminating in enhanced patient outcomes. This conference aims to provide a comprehensive update on recent TME research, emphasizing emerging areas and fostering collaboration among researchers from diverse disciplines.

## SESSION TOPIC HIGHLIGHTS

- Organ-Specific Microenvironments and Metastasis
- Systemic Macroenvironment and Metastasis: Effects of Aging and Stress
- The Metabolic Microenvironment, including Immune Metabolism
- Metabolic Macroenvironment: Obesity and Cancer Cachexia
- Stromal Changes as Tissue Becomes Tumor: The Expanding Functions of TME Components
- Multicellular Interactions within Tumor Immune Microenvironments
- Inflammation, the Immune Microenvironment, and the Systemic Interface
- Microbiome and Immune Therapy
- Therapy-Induced Changes in Organ-specific Microenvironment and Therapeutic Strategies for Targeting the TME




Continuing Medical Education (CME) Activity—*AMA PRA Category 1 Credits™* available

#AACRtumorenviro24  
AACR.org/TumorBody24

**AACR** American Association  
for Cancer Research®





AACR Special Conference in Cancer Research

# OPTIMIZING THERAPEUTIC EFFICACY AND TOLERABILITY THROUGH CANCER CHEMISTRY

IN ASSOCIATION WITH THE AACR CHEMISTRY IN CANCER WORKING GROUP (CICR)

December 9–11, 2024 | Hilton Toronto | Toronto, ON, Canada

**Abstract Deadline: September 24**

**Advance Registration Deadline: October 28**

## COCHAIRS



### **Philip Jones**

The University of Texas MD  
Anderson Cancer Center,  
Houston, TX



### **Angela N. Koehler**

Broad Institute of Harvard  
and MIT, Cambridge, MA



### **Chudi O. Ndubaku**

Paraza Pharma,  
Montreal, QC, Canada

## ABOUT THIS CONFERENCE

Discover breakthroughs in cancer chemistry at this exciting conference. Explore cutting-edge topics including safer therapeutic agents, drug combinability, nanoscale drug delivery, emerging targets, bivalent degraders, selective targeting, and other emerging topics.

## SESSION TOPIC HIGHLIGHTS

- Developing Efficacious Drugs with Better Combinability
- Drug Design and Optimization – Brain Penetration
- Drug Design and Optimization – New and Emerging Targets
- Emergence of Bivalent Degraders
- Engineered Nanoscale Drug Delivery Systems / Modern Formulation-Driven Approaches
- Innovations Opening Up the Potential for Safer Therapeutic Agents
- Selective Targeting: Gross Tissue-Restricting and Local (Non-Systemic) Administration (Small Molecule)

#AACRchem24  
AACR.org/CanChem24

**AACR** American Association  
for Cancer Research®



# SAN ANTONIO BREAST CANCER SYMPOSIUM®



December 10–13, 2024

Henry B. Gonzalez Convention Center | San Antonio, TX

**Early Registration Deadline: September 27**

**Advance Registration Deadline: November 1**

## CODIRECTORS



### **Carlos L. Arteaga**

UT Southwestern Medical  
Center, Dallas, TX



### **Virginia G. Kaklamani**

UT Health Science Center at San  
Antonio, San Antonio, TX

## ABOUT THIS CONFERENCE

The symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease to an international audience academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals.

## SESSION TOPIC HIGHLIGHTS

- Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction
- FDA Special Session: New Drug Approvals
- Sex, Drugs, Rock & Roll
- Dose Optimization in Breast Medical Oncology
- Mind the Gap in Breast Cancer in the Young
- Early Detection
- Clinical Case Discussions
- Clinical Controversies
- Unlocking New Targets with Molecular Degradors
- Case Based Clinical Approach to ER Positive Metastatic Breast Cancer
- Dissecting Disparities
- The Future of Cancer Genetics is Here
- Mind the Gap Breast Cancer in Older Adults
- Artificial Intelligence in the Clinic
- New Directions in Breast Cancer Prevention
- Debate: All Patients Should be Offered Universal Germline Genetic Testing
- View from the Trenches



Continuing Medical Education (CME) Activity–*AMA PRA Category 1 Credits™*  
available from the UT Health Science Center San Antonio



AACR Special Conference in Cancer Research

# TRANSLATING TARGETED THERAPIES IN COMBINATION WITH RADIOTHERAPY

IN ASSOCIATION WITH THE AACR PRECISION COMBINATION THERAPY TASK FORCE

January 26–29, 2025 | Hilton San Diego Bayfront | San Diego, CA

**Abstract Deadline: December 5, 2024**

**Advance Registration Deadline: January 28, 2025**

## COCHAIRS



**Silvia C. Formenti**

Weill Cornell Medicine,  
New York, NY



**Albert C. Koong**

The University of Texas  
MD Anderson Cancer Center,  
Houston, TX



**Quynh-Thu Le**

Stanford Cancer Institute,  
Stanford, CA


## ABOUT THIS CONFERENCE

Radiation therapy is a different “drug” depending on how it is given. There are varying effects on cell signaling within the tumor microenvironment depending on the dose and dose rate (FLASH radiation), and timing of the radiation given. Similarly, effects on normal tissue are variable depending on the dose per fraction. In addition, while most radiation therapy utilizes photons or electrons, proton and carbon ion therapy represent other modalities of radiation therapy with fundamentally different radiobiologic properties. Little is known about how emerging chemotherapy, targeted therapy, and immune therapy may be optimally given with the various forms of radiation therapy. This conference will bring together leading researchers within the fields of radiation biology, cancer biology, targeted agents, and cancer immunology to discuss how various combination therapies may be optimized to enhance treatment for patients.



Continuing Medical Education (CME) Activity—*AMA PRA Category 1 Credits™* available





AACR Special Conference in Cancer Research

# DNA METHYLATION, CLONAL HEMATOPOIESIS, AND CANCER

February 1-4, 2025 | The Westin San Diego Gaslamp Quarter | San Diego, CA

**Abstract Deadline: November 18, 2024**

**Advance Registration Deadline: December 20, 2024**

## COCHAIRS



### **Stephen B. Baylin**

Johns Hopkins University School  
of Medicine, Baltimore, MD



### **Margaret A. Goodell**

Baylor College of Medicine,  
Houston, TX



### **Peter A. Jones**

Van Andel Institute,  
Grand Rapids, MI

## ABOUT THIS CONFERENCE

This AACR Special Conference will integrate and highlight recent research regarding the central role of DNA methylation in human cancer. It is timed to celebrate the 25th Anniversary of a seminal AACR Special Conference on DNA Methylation, Imprinting, and the Epigenetics of Cancer that set the stage for many breakthroughs in this field and emphasized the role of DNA methylation in particular, rather than attempting to summarize research in the field of general chromatin biology such as histone modifications, etc.

## SESSION TOPIC HIGHLIGHTS

- Twenty-Five Years Later: New Concepts in Cancer Epigenetics
- Interpreting Methylation Signals
- DNA Methylation in a Chromatin Context
- Role of DNA Methylation and Hydroxymethylation in Immune Cell Function
- Clonal Hematopoiesis
- Normal and Abnormal Methylation Patterns and Detection
- New DNMTs, Combinations, and Responses



Continuing Medical Education (CME) Activity—*AMA PRA Category 1 Credits™* available

# AACR IO

## DISCOVERY AND INNOVATION IN CANCER IMMUNOLOGY: REVOLUTIONIZING TREATMENT THROUGH IMMUNOTHERAPY

February 23–26, 2025 | JW Marriott Los Angeles L.A. LIVE | Los Angeles, CA

### SCIENTIFIC COMMITTEE CHAIR



**Antoni Ribas**  
UCLA Jonsson  
Comprehensive Cancer  
Center, Los Angeles, CA

### ABOUT THIS CONFERENCE

This new major conference will encompass the very best of basic, translational, and clinical research in immunology, inflammation and immunotherapies for cancer, including immuno-oncology (IO) drugs, inflammatory modulators, vaccines, and cellular therapies. The cutting-edge AACR IO 2025 program will appeal to a wide audience of basic scientists, translational researchers, clinical investigators, regulators, industry, investors, and lay press. The spectrum of the IO field – including late-breaking clinical trials sessions highlighting new agents and IO combinations, and the results of practice-changing clinical trials will be covered.



Continuing Medical Education (CME) Activity-  
AMA PRA Category 1 Credits™ available

### KEYNOTE SPEAKERS\*

*\*Confirmed as of July 2024*



**James P. Allison**  
The University of Texas  
MD Anderson Cancer Center,  
Houston, TX



**Sangeeta N. Bhatia**  
MIT Koch Institute for  
Integrative Cancer Research,  
Cambridge, MA



**K. Christopher Garcia**  
Stanford University School of  
Medicine, Stanford, CA



**Carl H. June**  
University of Pennsylvania,  
Philadelphia, PA

#AACRIO25 | AACR.org/AACRIO

**Abstract Deadline: November 13, 2024**



**Late-Breaking Abstracts Open: January 16, 2025**

**Late-Breaking Abstract Deadline: January 23, 2025**

## PROGRAM HIGHLIGHTS

### Major Symposia Topics

- ▶ Cancer Immune Evasion
- ▶ CAR T Cells for Solid Tumors
- ▶ Inflammation and Cancer
- ▶ Myeloid Cell Checkpoints
- ▶ Neoadjuvant Immunotherapy
- ▶ New Roles of STING in Cancer Biology and Immunology
- ▶ Personalized Therapies Targeting Neoantigens

### Additional Session Topics

- ▶ CAR T Cells In Vivo Delivery
- ▶ Detection of Tumor-reactive T Cells
- ▶ Endogenous Retroviruses in the Anti-Tumor Immune Response (Dark Genome)
- ▶ Immune-Related Adverse Events in IO Therapy
- ▶ Microbiome
- ▶ Multi-Specific Antibodies and Antibody Fusion Proteins
- ▶ Oncolytic Viruses and Intratumoral Immunotherapies
- ▶ Spatial Organization of Immune Cells and Treatment with Immunotherapy
- ▶ Strategies to Overcome Manufacturing Challenges for Cell-Based Therapy
- ▶ T-cell Fitness, Dysfunction, and Exhaustion
- ▶ T-cell Therapies: Advances and Challenges
- ▶ Tertiary Lymphoid Structures in Cancer



### Crystal L. Mackall

Stanford University School of Medicine, Stanford, CA



### Gabriel A. Rabinovich

Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina



### Ton Schumacher

Netherlands Cancer Institute, Amsterdam, Netherlands



### Arlene H. Sharpe

Harvard Medical School, Boston, MA



### Jessica Stark

Massachusetts Institute of Technology, Cambridge, MA





AACR Special Conference in Cancer Research

# ACUTE LYMPHOBLASTIC LEUKEMIA

IN ASSOCIATION WITH THE AACR HEMATOLOGIC MALIGNANCIES WORKING GROUP

March 7–9, 2025 | Hilton San Diego Bayfront | San Diego, CA

**Abstract Deadline: December 30, 2024**

**Advance Registration Deadline: January 24, 2025**

## COCHAIRS



**Charles G. Mullighan**

St. Jude Children’s Research Hospital, Memphis, TN



**Elizabeth A. Raetz**

New York University Perlmutter Cancer Center, New York, NY



**Wendy Stock**

University of Chicago, Chicago, IL

## SESSION TOPIC HIGHLIGHTS

- CAR-T in Acute Lymphoblastic Leukemia (ALL)
- Targeted Immunotherapy in ALL
- Molecularly Targeted Therapies in ALL
- B-ALL Biology
- T-ALL Biology
- Future direction in ALL Therapy
- Survivorship and Disparities in ALL



Continuing Medical Education (CME) Activity–*AMA PRA Category 1 Credits™* available



AACR Special Conference in Cancer Research

# FUNCTIONAL AND GENOMIC PRECISION MEDICINE IN CANCER: DIFFERENT PERSPECTIVES, COMMON GOALS

March 11-13, 2025 | Hyatt Regency Boston | Boston, MA

**Abstract Deadline: November 15, 2024**

**Advance Registration Deadline: January 28, 2025**

## COCHAIRS



### **Anthony G. Letai**

Dana-Farber Cancer Institute,  
Boston, MA



### **Elaine R. Mardis**

The Institute for Genomic Medicine  
at Nationwide Children's Hospital,  
Columbus, OH



### **Peter Horak**

German Cancer Research Center,  
Heidelberg, Germany



### **Alice Soragni**

University of California,  
Los Angeles, CA

## ABOUT THIS CONFERENCE

The goal of this AACR Special Conference is to share experiences among those in the genomics and functional precision oncology arenas, to accelerate the progress toward routine clinical adoption of combined approaches in the oncology clinic. At this exciting program in Boston we will share technical, clinical, and logistical experiences, as well as our understanding of the barriers to widespread adoption of genomic and functional precision medicine in the treatment of the cancer patient, and how these approaches might be combined to provide more powerful tools than either alone.

## SESSION TOPIC HIGHLIGHTS

- Challenges of Intra-Tumor and Intra-Patient Heterogeneity for Precision Medicine
- Challenges in Tissue Acquisition and Handling for Precision Medicine
- Clinical Trial Design for Optimal Implementation of Precision Medicine
- Ex vivo Patient-Derived Models to Identify Biomarkers of Response
- Functional and Genomic Precision Medicine in Blood Cancers
- Functional and Genomic Precision Medicine in Solid Tumors
- Immunotherapy-predictive Biomarkers
- Machine Learning to Integrate Multiple Data Layers
- New Omics for Precision Medicine
- Vertebrate Models for Modeling Disease and Guiding Therapy



Continuing Medical Education (CME) Activity-AMA PRA Category 1 Credits™ available



# INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML)

IN COOPERATION WITH THE AMERICAN ASSOCIATION FOR CANCER RESEARCH® (AACR)

June 17–21, 2025 | Palazzo dei Congressi | Lugano, Switzerland

**Abstract Deadline: March 15, 2025**

**Advance Registration Deadline: February 28, 2025**

## ICML PRESIDENT



### **Franco Cavalli**

Institute of Oncology Research,  
Bellinzona, Switzerland

## ABOUT THIS CONFERENCE

The 18th ICML will once again present the latest results on diagnosis and treatment for all variants of tumors of the lymphatic system. ICML is the most important conference on malignant lymphomas in the world, attracting thousands of physicians and researchers from nearly 100 countries to Lugano.

## ORGANIZING COMMITTEE CHAIR



### **Francesco Bertoni**

Institute of Oncology Research,  
Bellinzona, Switzerland



**ICML**

**AACR**

American Association  
for Cancer Research®

# SHOP AACR. SUPPORT RESEARCH.



**AACR** American Association for Cancer Research® **SHOP**

[AACR.org/Shop](https://AACR.org/Shop)





# Become a Member.

## Join Us in the Global Conquest of Cancer.

### WHY YOU SHOULD JOIN

- Substantially reduced registration rates for AACR Annual Meetings and Special Conferences
- Privilege of sponsoring abstracts for AACR Annual Meetings
- Early access to housing reservations for AACR Annual Meetings
- Exclusive discounts on subscriptions to AACR journals
- No annual dues required for Associate membership and Student membership. Please visit **AACR.org/Membership** for more information on eligibility.
- Funding and award opportunities, including career development resources, research fellowships, scholar-in-training awards, and travel grants
- Professional development for early-career investigators and professionals, including education and professional advancement sessions
- Opportunities to network and join any of our Association and Scientific Working Groups
- Free online access to *Cancer Today* magazine
- Collaboration and resources through our AACR Scientist ↔ Survivor Program®



## The Essential Association for You and Your Colleagues!



Margaret Foti, PhD, MD (hc)  
AACR Chief Executive Officer



Patricia LoRusso, DO, PhD (hc), FAACR  
AACR President



**AACR**

American Association  
for Cancer Research®

Contact the AACR Membership and Professional  
Development Department with any questions at  
**[membership@aacr.org](mailto:membership@aacr.org)** or **215-440-9300**.



### OUR MISSION

The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research. Through its programs and services, AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Get social with us! @AACR



Cancer Research Catalyst <http://blog.aacr.org>